Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?

Intake of EPA and DHA for the management of morbid obesity in capsules

- Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein, cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of omega 3 capsules and placebo control.

Inclusion Criteria:

• Men and women aged between 18-65 years,
• BMI > 40 kg/m2 (or > 35 kg/m2 with comorbidities),
• ambulatory, receiving an oral diet,
• with a diagnosis of metabolic syndrome,
• and who signed a Term of Free and Informed Consent.

Exclusion Criteria:

• Systemic inflammatory response syndrome,
• coma or compromised organ,
• fever or infection foci,
• cancer with or without chemotherapy and radiotherapy,
• radiotherapy, inflammatory diseases of the gastrointestinal tract,
• transplant, trauma, surgery or hospital stay in the past 30 days
• use of steroids or non-steroid anti-inflammatory or immunomodulators agents or antibiotics,
• or those refusing to take part in the study.